글로벌 유전성 유방암 및 난소암 증후군 치료 시장 – 2030년까지의 산업 동향 및 예측

유전성 유방암 및 난소암 증후군 치료 시장 분석 및 규모

여러 의학 연구에 따르면 일반적인 암의 약 5%~10%가 유전성인 것으로 나타났습니다. 영향을 받은 사람들은 특정 암, 특히 남성과 여성 모두의 유방암과 여성의 난소암에 걸릴 위험이 더 높습니다. 영향을 받은 사람들은 보통 50세 이전에 암에 걸릴 가능성이 가장 높습니다. 흑색종, 전립선암, 췌장암과 같은 다른 유형의 암에 걸릴 위험도 약간 더 높습니다.

Data Bridge Market Research는 2023-2030년 예측 기간 동안 유전성 유방암 및 난소암 증후군 치료 시장의 성장률을 분석합니다. 유전성 유방암 및 난소암 증후군 치료 시장의 예상 CAGR은 언급된 예측 기간 동안 약 5.3%인 경향이 있습니다. 이 시장은 2022년에 62억 달러로 평가되었으며 2030년까지 93억 7천만 달러로 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

유전성 유방암 및 난소암 증후군 치료 시장 범위 및 세분화

Market Definition

Hereditary breast and ovarian cancer syndrome (HBOC) is a type of genetic disorder that increases the risk of ovarian, breast, and other cancers. This syndrome requires wide genetic counselling. Chemoprevention is also a possibility that is used widely for treatment. It can be caused by a mutation that is inherited in families. In this disease, a mutation in only 1 copy of the gene has an increased risk of getting that disease.  

Hereditary Breast And Ovarian Cancer Syndrome Treatment Market Dynamics

Drivers

• Rising Cases of Hereditary breast and ovarian cancer syndrome

The increasing incidence of hereditary breast and ovarian cancer syndrome is projected to enhance the market's growth rate. As per the Indian Council of Medical Research (ICMR), India is expected to have 17.3 lakh new cancer cases by 2020, with more than 8.8 lakh people dying from the disease. Furthermore, breast cancer, which has the highest occurrence of all cancers in women, has grown more common among those under the age of 50 years. Inherited genetic alterations can cause breast or ovarian cancer.

• Increased Demand of Newborn Screening

A consistent increase in demand for newborn screening has led to a rise in sales of DNA testing kits. Growing penetration of newborn screening globally is further helping in revenue growth. Several reforms in genetic testing recommendations have led to the inclusion of multigene panel testing for hereditary cancer into clinical practice. Furthermore, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for ovarian, breast and colorectal cancers provide information on some cancer risk factors and management. The Virginia Department of General Services Division of Integrated Laboratory Facilities screened around 7,867 newborns for more than 31 genetic and metabolic illnesses in November 2019. Thus, all these screening is boosting the growth of the market.  

Opportunities

• Rising Strategic Developments and Acquisitions

There are several strategies that are being developed to boost the demand of the market. One of the strategies is providing hereditary tests at a price lower than what is by competitors. For instance, Color Genomics began selling its product for USD 259, however products offered by Myriad cost about USD 4,000. The growing affordability of the tests is one of the major drivers of this segment. There have been acquisitions between market players that is helping in expanding the growth. For instance, Quest Diagnostics, which is a supplier of diagnostic information services, announced in January 2020, the all-cash equity acquisition of Blueprint Genetics. As its known that Blueprint Genetics focuses in gene variant interpretation using next-generation sequencing (NGS) and proprietary bioinformatics, with this deal, Quest and Blueprint Genetics will improve patient care and pharmaceutical R&D by growing access to important insights into genetic and rare disorders.

Restraints/Challenges

• Late Drug Approvals

The authorized organizations lead to late approvals of the proposed drugs that further lead to the decline of the market growth. The late approvals hamper the treatment processes thus restricting the growth.

This hereditary breast and ovarian cancer syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hereditary breast and ovarian cancer syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Hereditary Breast And Ovarian Cancer Syndrome Treatment Market

COVID-19 had a major impact on the market. For instance, after WHO declared COVID-19 a pandemic, governments globally declared lockdowns. The outbreak negatively impacted the inherited genetic analysis sector. This is because of the incapacity of genetic counsellors to observe clients in person, the high failure of doctors to provide guidance and the inability of the laboratory to do the tests. Additionally, genetic counselors were prohibited from working during government shutdowns because regulatory bodies such as the Centers for Medicaid Services (CMS) did not recognize them as healthcare practitioners.

Recent Development

• In 2022, Illumina, Inc. launched the in vitro diagnostic (IVD) kit, a cancer RNA sequencer. The release resulted in the development of the sequencing product line, which is followed by post market approval. It is anticipated to show a linear market growth

Global Hereditary Breast And Ovarian Cancer Syndrome Treatment Market Scope

The hereditary breast and ovarian cancer syndrome treatment market is segmented on the basis of diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Hormonal Therapy
• Chemoprevention
• Tamoxifen
• Others
• Genetic Counseling
• Medication
• Lynparza
• Talazoparib
• Rucaparib
• Niraparib
• Others

Diagnosis

• Genetic Testing
• Magnetic Resonance Imaging (MRI)
• Mammography
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

    Hereditary Breast And Ovarian Cancer Syndrome Treatment Regional Analysis/Insights

The hereditary breast and ovarian cancer syndrome treatment market is analyzed and market size insights and trends are provided by diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the hereditary breast and ovarian cancer syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

북미는 유전성 유방암 및 난소암 증후군 치료의 증가와 이 지역의 노령 인구 증가로 인해 예측 기간 동안 시장을 지배하고 있습니다. 게다가, 몇몇 주요 핵심 기업의 존재감 증가와 사람들의 건강에 해로운 생활 방식은 이 지역의 시장 성장률을 더욱 높일 것입니다.

아시아 태평양 지역은 이 지역에서 새로운 암 치료제의 침투가 증가하고 의료비가 증가함에 따라 향후 몇 년 동안 성장할 것으로 예상됩니다. 게다가 정부 주도의 이니셔티브가 증가함에 따라 이 지역의 시장 성장률이 더욱 높아질 것입니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 또한 글로벌 브랜드의 존재와 가용성, 그리고 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다. 

경쟁 환경 및 글로벌 유전성 유방암 및 난소암 증후군 치료 점유율 분석

유전성 유방암 및 난소암 증후군 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 위에 제공된 데이터 포인트는 유전성 유방암 및 난소암 증후군 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

유전성 유방암 및 난소암 증후군 치료 시장에서 활동하는 주요 기업은 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd.(이스라엘)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• GSK plc (영국)
• 노바티스 AG(스위스)
• Bayer AG(독일)
• 릴리(미국)
• 머크앤코(미국)
• 아스트라제네카(영국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 시플라 주식회사(미국)
• 애벗(미국)
• AbbVie Inc.(미국)
• 머크 KGaA(독일)
• LEO Pharma A/S(덴마크)
• Bausch Health Companies Inc. (캐나다)
• Sun Pharmaceutical Industries Ltd. (인도)
• Aurobindo Pharma(인도), Lupin(인도)
• 히크마 제약(영국)
• Fresenius Kabi AG(독일)
• Amneal Pharmaceuticals LLC. (미국)

SKU-68489